| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
---|
Phase N/A 1
2 3 4 Trials | | 0 | 12345678910 |
---|
| | | |
---|
| | | |
---|
| | | |
---|
Ahzantive (aflibercept-mrbb) / Amneal, Formycon, Coherus Oncology, Klinge Pharma, Teva, MS Pharma, Alvogen, Valorum Biologics | | | |
---|
| |
---|
| |
---|
| | | |
---|
| | | |
---|
Cimerli (ranibizumab-eqrn) / Amneal, Formycon, Coherus Oncology, Teva, Bio Usawa, Bioeq AG | | | |
---|
| |
---|
| |
---|
| | | |
---|
| | | |
---|
FYB206 (pembrolizumab biosimilar) / Formycon | | | |
---|
| |
---|
| |
---|
| | | |
---|
| | | |
---|
Otulfi (ustekinumab-aauz) / Formycon, Fresenius Kabi | | | |
---|
| |
---|
| |
---|
| | | |
---|
| | | |
---|
|